1958, BA in Biochemical Sciences, Harvard College; 1959, Fulbright Scholar, Scotland; 1963, Doctor of Medicine, Harvard Medical School. Over 30 years' research on understanding how growth factors regulate proliferation of cancer cells by activating receptors on cell surface; credited as first to design targeted cancer treatment that blocks oncogene-driven molecular pathways that control cell growth; pioneer in therapy of cancer with monoclonal antibodies and co-discoverer, in 1983, of Erbitux, an antibody approved for cancer therapy by FDA in 2004. 1970-85, Founding Director, NCI-designated cancer centre, UCSD. 1985-96, Chair, Department of Medicine and Pharmacology Program, Memorial Sloan-Kettering Cancer Center. 1996-2011, President, M.D. Anderson Cancer Center. Founding Editor-in-Chief, Clinical Cancer Research. Author of over 300 scientific articles, reviews and book chapters; senior editor of textbook, The Molecular Basis of Cancer. Recipient of numerous scientific awards for research achievements.